EMEA-003164-PIP01-21 - paediatric investigation plan

Bilastine
Pseudoephedrine
PIPHuman

Key facts

Active Substance
  • Bilastine
  • Pseudoephedrine
Therapeutic area
Pneumology-allergology
Decision number
P/0172/2022
PIP number
EMEA-003164-PIP01-21
Pharmaceutical form(s)
Prolonged-release tablet
Condition(s) / indication(s)
Treatment of allergic rhinitis
Route(s) of administration
Oral use
Contact for public enquiries

Faes Farma S.A.
Tel. +34 944818300
E-mail: ieguidazu@faes.es; mjarenal@faes.es

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page